94 related articles for article (PubMed ID: 9385130)
1. Tissue-specific estrogens--the promise for the future.
Fuleihan GE
N Engl J Med; 1997 Dec; 337(23):1686-7. PubMed ID: 9385130
[No Abstract] [Full Text] [Related]
2. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
Delmas PD; Bjarnason NH; Mitlak BH; Ravoux AC; Shah AS; Huster WJ; Draper M; Christiansen C
N Engl J Med; 1997 Dec; 337(23):1641-7. PubMed ID: 9385122
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene: a selective estrogen receptor modulator.
Scott JA; Da Camara CC; Early JE
Am Fam Physician; 1999 Sep; 60(4):1131-9. PubMed ID: 10507743
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of SERMs.
Dere WH
Aging (Milano); 1998 Apr; 10(2):160-1. PubMed ID: 9666217
[No Abstract] [Full Text] [Related]
5. A new alternative to estrogen: raloxifene.
Runowicz C
Health News; 1998 Jun; 4(8):4. PubMed ID: 9644506
[No Abstract] [Full Text] [Related]
6. Next generation of SERMs being seen in clinic.
Smigel K
J Natl Cancer Inst; 1997 Jul; 89(13):913. PubMed ID: 9214669
[No Abstract] [Full Text] [Related]
7. 'Smart' estrogens emerging.
Harv Heart Lett; 1998 Mar; 8(7):4-5. PubMed ID: 9516317
[No Abstract] [Full Text] [Related]
8. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.
Draper MW; Flowers DE; Huster WJ; Neild JA; Harper KD; Arnaud C
J Bone Miner Res; 1996 Jun; 11(6):835-42. PubMed ID: 8725181
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene: magic bullet for heart and bone?
Gustafsson JA
Nat Med; 1998 Feb; 4(2):152-3. PubMed ID: 9461183
[No Abstract] [Full Text] [Related]
10. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
[TBL] [Abstract][Full Text] [Related]
11. Raloxifene: designer estrogen for preventing postmenopausal osteoporosis.
Park L; Evans MF
Can Fam Physician; 1999 May; 45():1191-3. PubMed ID: 10349062
[No Abstract] [Full Text] [Related]
12. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
13. Raloxifene: a new class of anti-estrogens for the prevention of osteoporosis.
Kupecz D
Nurse Pract; 1998 Sep; 23(9):91-3. PubMed ID: 9778672
[No Abstract] [Full Text] [Related]
14. [Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis].
Hoszowski K
Pol Tyg Lek; 1995 Nov; 50(44-47):41-2. PubMed ID: 8643425
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
[TBL] [Abstract][Full Text] [Related]
16. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
Davies GC; Huster WJ; Shen W; Mitlak B; Plouffe L; Shah A; Cohen FJ
Menopause; 1999; 6(3):188-95. PubMed ID: 10486787
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
[TBL] [Abstract][Full Text] [Related]
18. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats.
Sato M; McClintock C; Kim J; Turner CH; Bryant HU; Magee D; Slemenda CW
J Bone Miner Res; 1994 May; 9(5):715-24. PubMed ID: 8053401
[TBL] [Abstract][Full Text] [Related]
19. Encouraging news from the SERM frontier. Selective estrogen receptor modulator.
Franks AL; Steinberg KK
JAMA; 1999 Jun; 281(23):2243-4. PubMed ID: 10376579
[No Abstract] [Full Text] [Related]
20. [Estrogen agonists, especially raloxifene, in the treatment of osteoporosis].
Lips P; Netelenbos JC
Ned Tijdschr Geneeskd; 1996 Jun; 140(23):1215-7. PubMed ID: 8700270
[No Abstract] [Full Text] [Related]
[Next] [New Search]
